Stevanato Group SpA (STVN) 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Reports Financial Results for the Second Quarter of 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group to Report Second Quarter 2024 Financial Results on August 6, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form SD - Specialized disclosure report

Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges

Cisterna’s site is the first to implement premium solutions outside the Group’s headquarters in Piombino Dese...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Announces Results of Annual General Meeting

-All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug...

Stevanato Group to Present at Upcoming Investor Conferences

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]